Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Azithromycin prevents airway complications of antibody deficiency

Publish date:: October 12, 2019

Key clinical point: Low-dose azithromycin prophylaxis reduces exacerbations and other respiratory events in primary airway deficiency.

Major finding: Relative to placebo over 2 years, low-dose azithromycin significantly reduced the annual rate of exacerbations by 1.6 episodes per patient.

Data Source: Phase 2 multicenter, placebo-controlled trial.

Disclosures: Dr. Milito reported no potential conflicts of interest.

Citation:

ERS 2019; Milito C et al. J Allergy Clin Immunol 2019;144: 584-593

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Immunology

Trial of epicutaneous immunotherapy in eosinophilic esophagitis,

Azithromycin prevents airway complications of antibody deficiency,

Ligelizumab Maintains Urticaria Control For Up to 1 Year,

Novel transplant regimen improves survival in primary immunodeficiency,

Penicillin Allergy & Risk of MRSA and C. difficle, BMJ; ePub 2018 Jun 27; Blumenthal, et al